文献速递肺外科

临床T1a非小细胞肺癌切除时强制淋巴结评估

Mandatory Nodal Evaluation During Resection of Clinical T1a Non-Small Cell Lung Cancers.
PubMed 文献 · Ann Thorac Surg · 2021-08-03

基于国家癌症数据库2004-2014年2157例≤1 cm临床T1a N0 M0非小细胞肺癌行肺叶切除加纵隔淋巴结评估的回顾性分析,发现6.7%存在隐匿性淋巴结转移(N1 5.1%,N2 1.6%),大细胞癌和分化差者风险高,建议T1a常规系统肺门纵隔淋巴结评估。

要点

  • ≤1 cm的T1a NSCLC隐匿性淋巴结转移率6.7%,N1占5.1%,N2占1.6%。
  • 大细胞癌和分化差/未分化者淋巴结转移风险显著升高。
  • 建议T1a NSCLC行系统肺门和纵隔淋巴结评估以准确分期。

核心结论

  • ≤1 cm的原发性NSCLC存在6.7%的隐匿性淋巴结病变,风险随组织学类型和分化程度增加。
  • 推荐对T1a NSCLC行强制系统性肺门和纵隔淋巴结评估,以准确分期和辅助治疗。

研究设计与样本

  • 回顾性队列研究,查询国家癌症数据库2004-2014年临床T1a N0 M0原发性NSCLC≤1 cm行肺叶切除加纵隔淋巴结评估的2157例。

主要发现

  • 2157例中6.7%有隐匿性淋巴结病变:5.1%为隐匿性N1,1.6%为N2。
  • 腺癌7.5%、大细胞癌25%、低分化11.8%或未分化/间变性25.0%的pN1和N2合计发生率高(P < .001)。
  • 单因素分析中,大细胞癌相对于腺癌的N1、N2、N1/N2比值比分别为4.31、3.62、4.12(均P < .05);间变性分级比值比分别为10.71、13.09、11.55。
  • 细支气管肺泡腺癌比值比最低(0.41、0.11、0.32),鳞状细胞癌N2比值比降低(0.29,均P < .05)。
  • 多因素分析仅细支气管肺泡腺癌相对于N0的pN2和N1/N2比值比降低,分级恶化对pN1和N1/N2仍显著(均P < .05)。

关键数值与推荐

  • 隐匿性淋巴结病变总率6.7%(N1 5.1%,N2 1.6%)。
  • 大细胞癌pN1/N2合计25%,低分化11.8%,未分化/间变性25.0%(P < .001)。
  • 大细胞癌vs腺癌N1、N2、N1/N2的OR分别为4.31、3.62、4.12(均P < .05)。
  • 间变性分级N1、N2、N1/N2的OR分别为10.71、13.09、11.55。
  • 细支气管肺泡腺癌N1、N2、N1/N2的OR分别为0.41、0.11、0.32;鳞癌N2的OR为0.29(均P < .05)。

临床怎么用

  • 对临床T1a N0 M0 NSCLC≤1 cm行肺叶切除时,应常规进行系统性肺门和纵隔淋巴结评估。
  • 组织学为大细胞癌或分化差/未分化时,应警惕隐匿性淋巴结转移风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recommendations for intraoperative lymph node evaluation are uniform regardless of whether a primary tumor is clinical T1a or T2a according to TNM 8th edition for stage I non-small cell lung cancer (NSCLC). We quantified nodal disease risk in patients with T1a disease (≤1 cm). METHODS: The National Cancer Database was queried for clinical T1a N0 M0 primary NSCLCs ≤1 cm undergoing lobectomy with mediastinal nodal evaluation from 2004-2014. Nodal disease risk was analyzed as a function of demographics and tumor characteristics. RESULTS: Among 2157 cases, 6.7% had occult nodal disease: 5.1% occult N1 and 1.6% N2. Adenocarcinoma (7.5%), large cell carcinoma (25%), and poor differentiation (11.8%) or undifferentiated/anaplastic (25.0%) had high rates of combined pN1 and N2 disease (P < .001). In univariable analysis, odds of pathologic N1, N2, or N1/N2 nodal disease with respect to N0 was greatest for large cell carcinoma (ref. adenocarcinoma odds ratio [OR] 4.31, 3.62, 4.12 respectively; all P < .05), and anaplastic grade (OR 10.71, 13.09, 11.55). Bronchoalveolar adenocarcinomas had the lowest odds (OR 0.41, 0.11, 0.32) and squamous cell carcinoma had lower odds for N2 (OR 0.29, all P < .05). In multivariable analysis only bronchoalveolar adenocarcinomas had lower odds of pathologic N2 and N1/N2 disease with respect to N0. Worsening grade remained significant for pathologic N1 and N1/N2 disease (both P < .05). CONCLUSIONS: A significant rate (6.7%) of occult nodal disease is present in primary NSCLCs ≤1 cm. Risk increases with certain histology and worsening grade. We recommend mandatory systematic hilar and mediastinal nodal evaluation for T1a NSCLC tumors for accurate staging and adjuvant therapy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Dezube AR, Mazzola E, Deeb A, et al. Mandatory Nodal Evaluation During Resection of Clinical T1a Non-Small Cell Lung Cancers. Ann Thorac Surg. 2021. PMID: 34358520. doi:10.1016/j.athoracsur.2021.06.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。